Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

MP07-66 is an inhibitor of the protein-protein interaction between SET and protein phosphatase 2A (PP2A) and a derivative of FTY720 (fingolimod; Item No. 11975).1 It increases PP2A activity in isolated human B cell chronic lymphocytic leukemia (B-CLL) cells when used at concentrations of 3 and 8 µM. Unlike FTY720, MP07-66 (8 µM) does not decrease plasma membrane levels of sphingosine-1-phosphate receptor 1 (S1P1) in isolated human B-CLL cells. MP07-66 induces apoptosis in isolated human B-CLL cells when used alone or in combination with dasatinib (Item No. 11498).
WARNING This product is not for human or veterinary use.
1. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-